Brown Advisory’s Global Blood Therapeutics, Inc. GBT Stock Holding History

Brown Advisory’s Portfolio GBT Stock Details GBT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-5,121	Closed	-$209K	–	1142
2021 Q1	$209K	Sell	5,121 -519,554	-99%	-$23.9M	﹤0.01%	1019
2020 Q4	$22.7M	Sell	524,675 -24,853	-5%	-$1.23M	0.04%	250
2020 Q3	$30.3M	Buy	549,528 +7,842	+1%	+$498K	0.06%	194
2020 Q2	$34.2M	Buy	541,686 +44,849	+9%	+$3.08M	0.08%	170
2020 Q1	$25.4M	Buy	496,837 +6,645	+1%	+$445K	0.08%	180
2019 Q4	$39M	Buy	490,192 +34,610	+8%	+$2.05M	0.1%	165
2019 Q3	$22.1M	Buy	455,582 +58,953	+15%	+$3.07M	0.06%	232
2019 Q2	$20.9M	Buy	396,629 +1,644	+0.4%	+$94.5K	0.06%	236
2019 Q1	$20.9M	Buy	394,985 +66,245	+20%	+$3.26M	0.06%	243
2018 Q4	$13.5M	Buy	328,740 +141,076	+75%	+$5.29M	0.05%	283
2018 Q3	$7.13M	Buy	+187,664	New	+$8.31M	0.02%	387

Other funds holding GBT

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Brown Advisory's GBT Position: Q2 2021 in Review

Brown Advisory sold out of Global Blood Therapeutics, Inc. (GBT) in Q2 2021, closing a stake of 5,121 shares — an estimated $209K sold.

Brown Advisory first reported a position in GBT in Q3 2018 and held it in 11 quarters. The position peaked at $39M in Q4 2019. 191 funds tracked by Wall St. Rank hold GBT as of Q2 2021.

Brown Advisory reported no remaining Global Blood Therapeutics, Inc. position as of Q2 2021 after selling out during the quarter.
Brown Advisory sold 5,121 Global Blood Therapeutics, Inc. shares in Q2 2021, an estimated $209K.
Brown Advisory first reported a position in Global Blood Therapeutics, Inc. in Q3 2018 and held it in 11 quarters.
Brown Advisory's Global Blood Therapeutics, Inc. position peaked at $39M in Q4 2019.
191 funds tracked by Wall St. Rank held Global Blood Therapeutics, Inc. as of Q2 2021.

Based on Brown Advisory's 13F filing for Q2 2021, filed 29 Jul 2021.